Forxiga is expected to be in competitive relationship with DPP-4 inhibitor on the patient's initial treatment regimen

On August 16, Ministry of Health and Welfare pre-announced insurance benefit range of 'Forxiga'. Its indication was limited to monotherapy or combination therapy with Metformin or Sulfonylurea family drug. Therefore, Forxiga is expected to be in competitive relationship with DPP-4 inhibitor on the patient's initial treatment regimen.

It was known that Astrazeneca which launched Forxiga submitt...